EP1689346A4 - Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants - Google Patents

Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Info

Publication number
EP1689346A4
EP1689346A4 EP04811773A EP04811773A EP1689346A4 EP 1689346 A4 EP1689346 A4 EP 1689346A4 EP 04811773 A EP04811773 A EP 04811773A EP 04811773 A EP04811773 A EP 04811773A EP 1689346 A4 EP1689346 A4 EP 1689346A4
Authority
EP
European Patent Office
Prior art keywords
methods
monoclonal antibodies
agonistic monoclonal
epha2 agonistic
epha2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04811773A
Other languages
German (de)
English (en)
Other versions
EP1689346A2 (fr
Inventor
Michael S Kinch
Kelly Carles-Kinch
Jane C Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Purdue Research Foundation
Original Assignee
MedImmune LLC
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC, Purdue Research Foundation filed Critical MedImmune LLC
Publication of EP1689346A2 publication Critical patent/EP1689346A2/fr
Publication of EP1689346A4 publication Critical patent/EP1689346A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04811773A 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants Withdrawn EP1689346A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52417703P 2003-11-20 2003-11-20
PCT/US2004/039112 WO2005051307A2 (fr) 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Publications (2)

Publication Number Publication Date
EP1689346A2 EP1689346A2 (fr) 2006-08-16
EP1689346A4 true EP1689346A4 (fr) 2007-11-21

Family

ID=34632874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04811773A Withdrawn EP1689346A4 (fr) 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Country Status (7)

Country Link
EP (1) EP1689346A4 (fr)
JP (1) JP4860477B2 (fr)
KR (1) KR20060135671A (fr)
CN (1) CN1905899B (fr)
AU (1) AU2004293034B2 (fr)
CA (1) CA2546763A1 (fr)
WO (1) WO2005051307A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
WO2003099313A1 (fr) 2002-05-23 2003-12-04 Purdue Research Foundation Tyrosine phosphatase de faible poids moleculaire (lmw-ptp) servant de cible a usage diagnostique et therapeutique
JP2006521111A (ja) 2003-03-12 2006-09-21 バスジーン セラピューティクス, インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
KR20070034465A (ko) 2004-03-12 2007-03-28 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
ES2529451T3 (es) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
CA2633718A1 (fr) * 2005-12-21 2007-07-05 Medimmune, Llc Anticorps agonistes d'epha2 a affinites optimisees et methodes d'utilisation de ces anticorps
EP2069795A4 (fr) * 2007-06-18 2010-10-06 Medimmune Llc Traitement synergique de cellules qui expriment epha2 et erbb2
EP2185594B1 (fr) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanisés qui se lient à ephb4
TWI443109B (zh) * 2007-08-30 2014-07-01 Daiichi Sankyo Co Ltd 抗epha2抗體
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012012759A2 (fr) * 2010-07-22 2012-01-26 The Regents Of The University Of California Anticorps-antigènes antitumoraux et méthodes d'utilisation correspondantes
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016171242A1 (fr) * 2015-04-24 2016-10-27 第一三共株式会社 Détection d'epha2
CN115025217B (zh) * 2022-05-13 2023-05-05 广东齐美医药生物科技集团有限公司 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2003094859A2 (fr) * 2002-05-10 2003-11-20 Medimmune, Inc. Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
WO2005056766A2 (fr) * 2003-12-04 2005-06-23 Medimmune, Inc. Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2003094859A2 (fr) * 2002-05-10 2003-11-20 Medimmune, Inc. Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
US20040091486A1 (en) * 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2005056766A2 (fr) * 2003-12-04 2005-06-23 Medimmune, Inc. Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU MIN ET AL: "Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 1234, XP008079516, ISSN: 0197-016X *
HU MIN ET AL: "EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.", MOLECULAR CANCER RESEARCH : MCR OCT 2004, vol. 2, no. 10, October 2004 (2004-10-01), pages 533 - 540, XP002435680, ISSN: 1541-7786 *
LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1475-4029 *
MILLER KATHY D ET AL: "EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, no. Suppl. S, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 132, XP002435681, ISSN: 0197-016X *

Also Published As

Publication number Publication date
KR20060135671A (ko) 2006-12-29
WO2005051307A3 (fr) 2006-09-08
WO2005051307A2 (fr) 2005-06-09
AU2004293034A1 (en) 2005-06-09
JP4860477B2 (ja) 2012-01-25
CA2546763A1 (fr) 2005-06-09
CN1905899B (zh) 2011-09-28
EP1689346A2 (fr) 2006-08-16
CN1905899A (zh) 2007-01-31
AU2004293034B2 (en) 2012-02-02
JP2008500021A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
EP1689346A4 (fr) Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
HK1219487A1 (zh) 特異抗體及使用它們的方法
SG10201606980VA (en) Anti-cd3 antibodies and methods of use thereof
IL179102A (en) Human-specific fcγriib antibodies and methods for their use
HK1208472A1 (en) Antibodies that bind cell-associated ca 125/o722p and methods of use thereof ca125/o772p
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
EP1614693A4 (fr) Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
IL175935A0 (en) Solid forms of anti-egfr antibodies
EP1833849A4 (fr) Anticorps specifiques de fc gamma riib et leurs procedes d'utilisation
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (fr) Anticorps monoclonal et utilisation de celui-ci
EP1633785A4 (fr) Anticorps monoclonaux humains diriges contre l'antigene protecteur de bacillus anthracis
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
IL205511A0 (en) Methods and compositions for the production of monoclonal antibodies
EP1812065A4 (fr) Anticorps d'affinité élevée contre la hmgb1 et procédés d'utilisation
IL174016A (en) Monoclonal antibodies to m-csf and their uses
HK1098825A1 (en) Human monoclonal antibodies against cd20
IL149701A0 (en) Use of anti-ctla-4 antibodies
EP1572077A4 (fr) Utilisations d'anticorps 8h9 monoclonaux
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL182943A0 (en) Ovr110 antibody compositions and methods of use
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
EP1968998A4 (fr) Anticorps agonistes d'epha2 à affinités optimisées et méthodes d'utilisation de ces anticorps

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060620

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20061031BHEP

Ipc: C07K 16/28 20060101ALI20061031BHEP

Ipc: C12P 21/08 20060101ALI20061031BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/20 20060101ALI20071004BHEP

Ipc: C12N 15/63 20060101ALI20071004BHEP

Ipc: C12N 15/13 20060101ALI20071004BHEP

Ipc: A61P 35/00 20060101ALI20071004BHEP

Ipc: C07H 21/04 20060101ALI20071004BHEP

Ipc: C07K 16/28 20060101ALI20071004BHEP

Ipc: C12P 21/08 20060101ALI20071004BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071019

17Q First examination report despatched

Effective date: 20080619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081230